“The development of TE-6168, the novel thrombolytic fusion protein” was selected as a significant case of the Center for Drug […]
Immunwork, Inc., a subsidiary of T-E Pharma, today announced the successful completion of the Phase 1/2a clinical trial of its
“The development of the novel drug, TE-1146, the CD38 specific antibody drug conjugate (ADC)” was selected as a significant case
• Pioneering Patient Experience: TE-8214, a highly water-soluble aqueous solution, enables pain-free subcutaneous injection with a thin 30G needle, eliminating injection
Immunwork announced that two ultra-long-acting drugs developed using innovative fatty acid bundles technology platform have received approval from the Australian
“The development of the novel drug, TE-8105, the glucagon-like peptide-1 receptor agonist” was selected as a significant case of the
